tradmap

TNGX Earnings Tango Therapeutics, Inc.

Reported EPS, revenue and net income by fiscal period (SEC EDGAR) — quarterly and annual. Full financials → Chart & overview → Updated

Annual results

Diluted EPS (annual)
-$1 -$1 $0 2021 2022 2023 2024 2025
EPS
Revenue (annual)
$0 $31M $62M 2020 2021 2022 2023 2024 2025
Revenue
Net income (annual)
-$130M -$65M $0 2020 2021 2022 2023 2024 2025
Net income

Quarterly results

Diluted EPS (quarterly)
-$1 -$0 $0 Q3 '22 Q2 '23 Q1 '24 Q3 '24 Q2 '25 Q1 '26
EPS
Revenue (quarterly)
$0 $27M $54M Q3 '23 Q1 '24 Q3 '24 Q1 '25 Q3 '25 Q1 '26
Revenue
Net income (quarterly)
-$55M -$20M $16M $0 Q3 '23 Q1 '24 Q3 '24 Q1 '25 Q3 '25 Q1 '26
Net income

Reported EPS history

1–21 of 21
Q2 20262026-06-30-0.682026-08-1110-Q
Q1 20262026-03-31-0.322026-05-1310-Q
FY 20252025-12-31-0.872026-03-0510-K
Q3 20252025-09-30-0.572025-11-0410-Q
Q2 20262025-06-30-0.712026-08-1110-Q
Q1 20262025-03-31-0.362026-05-1310-Q
FY 20252024-12-31-1.192026-03-0510-K
Q3 20252024-09-30-0.852025-11-0410-Q
Q2 20252024-06-30-0.582025-08-0510-Q
Q1 20252024-03-31-0.352025-05-1210-Q
FY 20252023-12-31-1.082026-03-0510-K
Q3 20242023-09-30-0.782024-11-0610-Q
Q2 20242023-06-30-0.552024-08-0710-Q
Q1 20242023-03-31-0.322024-05-0810-Q
FY 20242022-12-31-1.232025-02-2710-K
Q3 20232022-09-30-0.902023-11-0810-Q
Q2 20232022-06-30-0.572023-08-0710-Q
Q1 20232022-03-31-0.292023-05-0910-Q
FY 20222021-12-31-0.942023-03-2710-K
Q3 20222021-09-30-0.682022-11-1010-Q
Q2 20222021-06-30-0.372022-08-1010-Q

Source: SEC EDGAR / XBRL (reported actuals; no consensus estimates). Some issuers (e.g. mortgage REITs, banks) don't report a conventional revenue line, so those charts may be omitted. Informational only — not financial advice.